RESUMO
Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39+ months. Menogaril displays little activity in patients with previously treated MM.
Assuntos
Antineoplásicos/administração & dosagem , Mieloma Múltiplo/tratamento farmacológico , Nogalamicina/análogos & derivados , Antineoplásicos/efeitos adversos , Esquema de Medicação , Avaliação de Medicamentos , Humanos , Menogaril , Nogalamicina/administração & dosagem , Nogalamicina/efeitos adversosRESUMO
Beta interferon (beta-IFN) and interleukin-2 (IL-2) have been utilized in experimental cancer therapy because of their effects on the immune system. We report here a patient treated with IL-2 and beta-IFN who rapidly developed an immune-mediated, bullous exfoliative dermatitis and who ultimately died. Various etiologic mechanisms are proposed.
Assuntos
Interferon Tipo I/efeitos adversos , Interleucina-2/efeitos adversos , Leucemia Linfocítica Crônica de Células B/terapia , Pênfigo/induzido quimicamente , Humanos , Interferon Tipo I/uso terapêutico , Interleucina-2/uso terapêutico , Masculino , Pessoa de Meia-IdadeRESUMO
Forty-nine patients with advanced carcinoma of the breast who had received no prior chemotherapy were randomized to receive either high-dose cyclophosphamide (C) 1250 mg/M2 intravenously on day 1 and 5-fluorouracil (F) 600 mg/M2 intravenously on days 1 through 5 (CF), or vincristine (V) 1.5 mg/M2, doxorubicin (A) 50 mg/M2 and cyclophosphamide (C) 500 mg/M2 (VAC), all intravenously on day 1. Both regimens were repeated at 3-week intervals. Nine of 25 patients (36%) treated with CF and ten of 21 patients (48%) treated with VAC showed a complete or partial response as defined by the (UICC) guidelines. The estimated median time to progression for all patients was 3.5 months for CF and 6.0 months for VAC, with the median time to progression for responding patients being 8.5 months on CF and 6.3 months on VAC. Estimated survival is also similar for the two regimens. Ten of the patients treated with high-dose CF experienced septic episodes and four died. Toxicity on the CF arm necessitated premature closure of the study, and thus full statistical comparison of the efficacy of the two regimens cannot be made.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Ensaios Clínicos como Assunto , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Seguimentos , Humanos , Metástase Neoplásica , Vincristina/administração & dosagemRESUMO
A father and son hairy cell leukemia are identified on the basis of tartrate-resistant acid-phosphatase-positive hairy cells and diagnostic bone core biopsies. Personal interviews of the two patients revealed no evidence of consanguinity, primary immune deficiency, or common medication use. HLA typing revealed both patients to be A1,3 and B8,14.
Assuntos
Leucemia de Células Pilosas/genética , Fosfatase Ácida/sangue , Idoso , Contagem de Células Sanguíneas , Medula Óssea/patologia , Teste de Histocompatibilidade , Humanos , Leucemia de Células Pilosas/sangue , Leucemia de Células Pilosas/patologia , Masculino , Pessoa de Meia-IdadeRESUMO
Twenty-eight patients with disseminated malignant melanoma were treated with DTIC (250 mg/m2 iv, Days 1--5) and actinomycin D (0.5 mg/day iv, Days 1--5) at 5-week intervals. Patients were randomly allocated to receive no immunotherapy or immunotherapy consisting of methanol extracted residue of bacillus Calmette-Guérin (0.5 mg intradermally; 100 microgram in five separate sites) every 5 weeks, concomitant with chemotherapy. Of these 28 evaluable patients, 13 received chemoimmunotherapy with one complete response (CR) and 15 received chemotherapy alone with one CR. Both responses occurred in lymph node metastases. No partial responses were seen.